Latest from Montefiore Health System

An analysis of ACHIEVE II suggests that the oral CGRP antagonist from Allergan provides significant pain freedom and relief of the most bothersome symptoms for adults with migraine for at least one dose assessed.
Data show patients with high frequency episodic migraine are comparable to those with chronic migraine in regard to chronicity and disability.
Eli Lilly’s lasmiditan (Reyvow) tablets are the first member of the ditan class approved for use in adults with migraine with or without aura, offering patients who have an inadequate response to other therapies a new acute treatment option.
New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care. 
Montefiore Health System will also be working with The American Journal for Managed Care.
The director of the Montefiore Headache Center will provide further insight into migraine care at the 1st Annual International Congress on the Future of Neurology, to be held September 27-28 in New York City.
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center will offer further insights on narcolepsy at the upcoming International Congress on the Future of Neurology, September 27-28, 2019 in New York City.
SAP Partner Banner